The other example, which may actually have a greater effect on IGF2 cancer-related effects, relates to Paxillin, a focal adhesion protein found to bear unexploited nuclear functions as a chromatin interacting co-factor, specifically affecting a number of genes; in particular, Paxillin has been found to activate IGF2 transcriptional activation by stimulating the interaction between the enhancer region and the IGF2 promoters while restraining the interaction between the enhancer and H19 via downregulation of it gene [102]. The gene discussed is H19; the disease is cancer.